Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02842138|
Recruitment Status : Unknown
Verified February 2019 by Jun Zhu, Peking University.
Recruitment status was: Active, not recruiting
First Posted : July 22, 2016
Last Update Posted : February 25, 2019
Marino Biotechnology Co., Ltd.
Information provided by (Responsible Party):
Jun Zhu, Peking University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Actual Primary Completion Date :||February 28, 2018|
|Estimated Study Completion Date :||August 2019|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Guo X, Liu H, Ding N, Zhang T, Duan P, Lin Y, Zheng W, Wang X, Lin N, Tu M, Xie Y, Zhang C, Liu W, Deng L, Gao S, Ping L, Wang X, Zhou N, Zhang J, Wang Y, Lin S, Mamuti M, Yu X, Fang L, Wang S, Song H, Wang G, Jones L, Zhu J, Chen SY. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019 Jun;25(6):947-953. doi: 10.1038/s41591-019-0421-7. Epub 2019 Apr 22.